Clinical trials: Motor Fluctuations
Parkinson Disease
Study of CVN424 in Parkinson's Disease Patients With Motor Fluctuations
This is a phase 2 study, randomized, double-blind, placebo-controlled, multicenter study of oral CVN424 at two dose levels (low-dose and high-dose) in Parkinson's disease (PD) patients with motor fluctuations.
- Trial name
- NCT04191577
- Testing
- CVN424 Low Dose, CVN424 High Dose
- Where
- 21 sites in United States
- Volunteers
- 136 people
- Sponsor
- Cerevance Beta, Inc.
Parkinson Disease
OpiCapone Effect on Motor Fluctuations and pAiN
The aim of this study is to investigate the efficacy of 50 mg opicapone when administered with the existing treatment of levodopa (L-dopa) plus a dopa decarboxylase inhibitor (DDCI), in Parkinson's disease (PD) patients with…
- Trial name
- OCEAN (NCT04986982)
- Testing
- Opicapone 50 mg
- Where
- United Kingdom
- Volunteers
- 144 people
- Sponsor
- Bial - Portela C S.A.
Parkinson's Disease
Continuous Application of Lisuride in Parkinson's Disease by Subcutaneous Infusion
The aim of the study is to evaluate the long-term efficacy, local tolerability and safety of Lisuride applied as subcutaneous infusion compared to placebo in patients with advanced Parkinson's disease with motor fluctuations and…
- Trial name
- NCT00408915
- Testing
- Continuous Subcutaneous Lisuride Infusion
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- Axxonis Pharma AG
Parkinson's Disease With Motor Fluctuations
Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations
The purpose of this study is to evaluate the long term safety and tolerability of PF-06649751 in Parkinson's disease patients who experience motor-fluctuations.
- Trial name
- NCT03185481
- Testing
- 1 mg QD to 15 mg QD PF-06649751, 3 mg QD to 15 mg QD PF-06649751, 7 mg QD to 15 mg QD PF-06649751
- Where
- 9 sites in United States
- Volunteers
- 5 people
- Sponsor
- Pfizer
Advanced Stage Parkinson's Disease
SLV308 for Treatment of Patients With Parkinson's Disease Experiencing Motor Fluctuations
This study is a multicenter, randomized, double blind, parallel group study of 3 months' treatment with SLV308 administered as a monotherapy in patients with advance stage PD.
- Trial name
- NCT00406588
- Testing
- Levodopa (Pardoprunox)
- Where
- 87 sites in United States, Argentina and 10 more
- Volunteers
- 295 people
- Sponsor
- Solvay Pharmaceuticals
Parkinson's Disease
DNS-7801 vs. Placebo in Parkinson's Disease
This is a randomized, double-blind, two-part placebo-controlled parallel group outpatient treatment study that will utilize standard Parkinson's Disease measures to evaluate the effect of DNS-7801
- Trial name
- PRIORITY (NCT03306329)
- Testing
- DNS-7801 (low-dose), DNS-7801 (high dose)
- Where
- 9 sites in United States
- Volunteers
- 5 people
- Sponsor
- Dart NeuroScience, LLC
Advanced Parkinson's Disease
Observational Study Evaluating Long-Term Effectiveness of Duodopa/Duopa in Patients With Advanced Parkinson's Disease
This study is a non-interventional post-marketing observational study (PMOS) of participants with advanced Parkinson's disease (PD) treated with Duodopa/Duopa in a routine clinical setting.
- Trial name
- DUOGLOBE (NCT02611713)
- Where
- 54 sites in United States, Australia and 8 more
- Volunteers
- 213 people
- Sponsor
- AbbVie
Dyskinesias, Parkinson's Disease
Safety/Efficacy Study of Levodopa-Carbidopa Intestinal Gel in Parkinson's Subjects
Long term safety and efficacy (12 months) of levodopa-carbidopa intestinal gel.
- Conditions
- Dyskinesias, Parkinson's Disease, Severe Motor Fluctuations
- Trial name
- NCT00360568
- Testing
- Levodopa-carbidopa intestinal gel, CADD-Legacy® 1400 ambulatory infusion pump, PEG tube
- Where
- 22 sites in United States, Germany and 1 more
- Volunteers
- 62 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Parkinson's Disease (PD)
Study Comparing Continuous Subcutaneous Infusion Of ABBV-951 With Oral Carbidopa/Levodopa Tablets For Treatment Of Motor Fluctuations In Adult Participants With Advanced Parkinson's Disease
Parkinson's disease (PD) is a neurological condition, which affects the brain. PD gets worse over time, but how quickly it progresses varies a lot from person to person.
- Trial name
- NCT04380142
- Testing
- ABBV-951, Levodopa/Carbidopa (LD/CD)
- Where
- 76 sites in United States, Australia
- Volunteers
- 174 people
- Sponsor
- AbbVie
Parkinson's Disease
A Study to Evaluate the Efficacy and Safety of HRG2010 in Parkinson's Disease With Motor Fluctuations
The study is a multicenter, randomized, double-blind, double-dummy, active-controlled, Phase III clinical study. The aim of this trial is to evaluated the efficacy and assessed the safety of HRG2010 compared with a…
- Trial name
- NCT06596876
- Where
- China
- Volunteers
- 165 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Parkinson Disease
A Randomized, Double-blind, Placebo-controlled, Five Parallel Groups Efficacy and Safety Study of NS 2330 (Tesofensine) (0.125 mg, 0.25 mg, 0.5 mg and 1.0 mg) Administered Orally Once Daily Over 14 Weeks in Levodopa Treated Parkinson Patients With Motor Fluctuations
The primary objective of this exploratory study is to investigate the efficacy and safety of tesofensine in daily doses (from 0.125 mg to 1.0 mg) in comparison to placebo, over a 14-week treatment period in levodopa treated…
- Trial name
- NCT00148512
- Testing
- 1. Tesofensine (NS 2330)
- Where
- 50 sites in Austria, France and 4 more
- Volunteers
- 254 people
- Sponsor
- Boehringer Ingelheim
Advanced Parkinson's Disease
Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects
The primary objective of this study was to demonstrate the superiority of levodopa - carbidopa intestinal gel over treatment with optimized oral levodopa/carbidopa during 12 weeks.
- Trial name
- NCT00357994
- Testing
- Levodopa carbidopa intestinal gel (LCIG), Levodopa carbidopa (LC) oral encapsulated immediate release (IR) tablets, CADD-Legacy® 1400 ambulatory infusion pump
- Where
- 15 sites in United States, Germany
- Volunteers
- 36 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Parkinson's Disease
A Study of E2007 In Patients With Parkinson's Disease
Phase IIb open-label extension study for patients with Parkinson's Disease. All patients will receive active study drug. The study will involve outpatient visits only.
- Trial name
- NCT00427011
- Testing
- E2007
- Where
- 9 sites in United States
- Volunteers
- 25 people
- Sponsor
- Eisai Inc.
Parkinson's Disease
Multicentre Study in Four Parallel Groups of Parkinson's Disease (PD) Patients
The purpose of this study is to investigate the tolerability and the effect of BIA 9-1067 at steady-state on the levodopa pharmacokinetics in Parkinson's Disease (PD) patients treated with levodopa/dopa-decarboxylase inhibitor.
- Trial name
- NCT01568047
- Testing
- BIA 9-1067, Levodopa/Carbidopa, Levodopa/Benzerazide
- Where
- 7 sites in Romania, Ukraine
- Volunteers
- 40 people
- Sponsor
- Bial - Portela C S.A.
Parkinson Disease
Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson's Disease
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, fixed-dose study in patients with a diagnosis of Parkinson's Disease consistent with the UK Parkinson's Disease Society (UKPDS) Brain Bank…
- Trial name
- NCT05766813
- Testing
- Lenrispodun
- Where
- 35 sites in United States
- Volunteers
- 79 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Parkinson's Disease
18-month Study of Long-term Efficacy & Safety of Safinamide as add-on Therapy in Patients With Mid-late Stage PD
The purpose of this study is to determine the long-term efficacy and safety of two doses of safinamide (50 and 100 mg/day, p.o), compared to placebo, as add-on therapy in patients with idiopathic Parkinson's disease with motor…
- Trial name
- NCT01286935
- Testing
- Safinamide
- Volunteers
- 544 people
- Sponsor
- Newron Pharmaceuticals SPA
Parkinson's Disease
Rasagiline in Advanced Parkinson's Disease Patients With Motor Fluctuations Treated With Levodopa/Carbidopa Therapy.
Study to look at the effectiveness, tolerability and safety of two doses of Rasagiline (0.5 mg and 1mg) in advanced Parkinson's Disease (PD) Patients who have been treated with Levodopa/Carbidopa therapy.
- Trial name
- NCT00203177
- Testing
- rasagiline mesylate, rasagiline mesylate 1.0 mg
- Where
- 8 sites in United States, Canada
- Volunteers
- 254 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Idiopathic Parkinson Disease
Safety and Tolerability of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients With Parkinson's Disease.
Phase 3, international, multicenter, open-label 12 month safety study.
- Trial name
- NCT03051607
- Testing
- Tozadenant
- Where
- 35 sites in United States, Canada and 1 more
- Volunteers
- 66 people
- Sponsor
- Biotie Therapies Inc.
Idiopathic Parkinson's Disease
Efficacy and Safety Study of Inhaled CVT 301 in Parkinson's Disease Patients for Treatment of OFF Episodes
This randomized, multicenter, placebo-controlled, double-blind study will evaluate the efficacy and safety of inhaled CVT 301 compared with placebo in PD patients experiencing motor response fluctuations (OFF phenomena) as an…
- Trial name
- NCT01777555
- Testing
- CVT-301
- Where
- 22 sites in United States, Italy and 2 more
- Volunteers
- 89 people
- Sponsor
- Acorda Therapeutics